10,892 Shares in Halozyme Therapeutics, Inc. $HALO Purchased by Fairvoy Private Wealth LLC

Fairvoy Private Wealth LLC acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 10,892 shares of the biopharmaceutical company’s stock, valued at approximately $1,202,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CoreCap Advisors LLC raised its stake in Halozyme Therapeutics by 98.0% during the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 150 shares during the period. MidFirst Bank purchased a new position in Halozyme Therapeutics during the second quarter valued at approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Halozyme Therapeutics during the second quarter valued at approximately $28,000. Quantbot Technologies LP bought a new position in shares of Halozyme Therapeutics in the second quarter worth approximately $30,000. Finally, Mather Group LLC. boosted its position in shares of Halozyme Therapeutics by 48.9% in the third quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 136 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of analyst reports. TD Cowen increased their price objective on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Citizens Jmp raised their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. Zacks Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 13th. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.55.

Halozyme Therapeutics Price Performance

HALO traded up $0.66 during trading on Monday, reaching $122.50. 1,894,130 shares of the company traded hands, compared to its average volume of 1,944,203. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $123.60. The firm has a fifty day simple moving average of $109.06 and a 200 day simple moving average of $85.08. The company has a market cap of $13.90 billion, a P/E ratio of 36.57, a PEG ratio of 0.46 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter last year, the business posted $1.54 earnings per share. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director directly owned 40,418 shares in the company, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 18,996 shares of the business’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the sale, the director owned 58,839 shares in the company, valued at approximately $6,339,313.86. The trade was a 24.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 125,852 shares of company stock worth $13,538,046. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.